CD271⁺ subpopulation of pancreatic stellate cells correlates with prognosis of pancreatic cancer and is regulated by interaction with cancer cells.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Carcinoma, Pancreatic Ductal/*pathology ; Nerve Tissue Proteins/*metabolism ; Pancreatic Neoplasms/*pathology ; Pancreatic Stellate Cells/*metabolism ; Receptors, Nerve Growth Factor/*metabolism; Adult ; Aged ; Aged, 80 and over ; Animals ; Carcinoma, Pancreatic Ductal/metabolism ; Carcinoma, Pancreatic Ductal/mortality ; Cell Communication ; Cell Movement ; Coculture Techniques ; Female ; Gene Expression ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Mice ; Mice, SCID ; Middle Aged ; Neoplasm Transplantation ; Nerve Tissue Proteins/genetics ; Pancreatic Neoplasms/metabolism ; Pancreatic Neoplasms/mortality ; Prognosis ; Proportional Hazards Models ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Receptors, Nerve Growth Factor/genetics ; Stromal Cells/metabolism ; Tumor Cells, Cultured ; Tumor Microenvironment
    • Abstract:
      Pancreatic stellate cells (PSCs) play a crucial role in the aggressive behavior of pancreatic cancer. Although heterogeneity of PSCs has been identified, the functional differences remain unclear. We characterized CD271⁺ PSCs in human pancreatic cancer. Immunohistochemistry for CD271 was performed for 31 normal pancreatic tissues and 105 pancreatic ductal adenocarcinomas (PDACs). We performed flow cytometry and quantitative RT-PCR, and assessed CD271 expression in PSCs isolated from pancreatic tissues and the changes in CD271 expression in PSCs cocultured with cancer cells. We also investigated the pattern of CD271 expression in a SCID mouse xenograft model. In the immunohistochemical analyses, the CD271-high staining rates in pancreatic stroma in normal pancreatic tissues and PDACs were 2/31 (6.5%) and 29/105 (27.6%), respectively (p = 0.0069). In PDACs, CD271⁺ stromal cells were frequently observed on the edge rather than the center of the tumors. Stromal CD271 high expression was associated with a good prognosis (p = 0.0040). Flow cytometric analyses demonstrated CD271-positive rates in PSCs were 0-2.1%. Quantitative RT-PCR analyses revealed that CD271 mRNA expression was increased in PSCs after coculture with pancreatic cancer cells. However, the level of CD271 mRNA expression subsequently decreased after the transient increase. Furthermore, CD271 mRNA expression was decreased in PSCs migrating toward pancreatic cancer cells through Matrigel. In the xenograft model, CD271⁺ PSCs were present at tumor margins/periphery and were absent in the tumor core. In conclusion, CD271 was expressed in PSCs around pancreatic tumors, but not in the center of the tumors, and expression decreased after long coculture with pancreatic cancer cells or after movement toward pancreatic cancer cells. These findings suggest that CD271⁺ PSCs appear at the early stage of pancreatic carcinogenesis and that CD271 expression is significantly correlated with a better prognosis in patients with PDAC.
    • References:
      Cancer Res. 2010 Nov 1;70(21):8319-28. (PMID: 20837666)
      Cancer Res. 2004 May 1;64(9):3215-22. (PMID: 15126362)
      Nat Rev Cancer. 2004 Nov;4(11):839-49. (PMID: 15516957)
      Growth Factors. 2009 Oct;27(5):289-99. (PMID: 19639490)
      Mol Vis. 2008 Mar 04;14:431-42. (PMID: 18334960)
      Nature. 2004 Nov 18;432(7015):332-7. (PMID: 15549095)
      Gastroenterology. 1998 Aug;115(2):421-32. (PMID: 9679048)
      Nature. 2010 Jul 1;466(7302):133-7. (PMID: 20596026)
      Gastroenterology. 2005 Apr;128(4):907-21. (PMID: 15825074)
      J Histochem Cytochem. 1988 Apr;36(4):383-9. (PMID: 2831267)
      Ann N Y Acad Sci. 2007 Jun;1106:262-71. (PMID: 17395729)
      Pancreas. 2004 Oct;29(3):179-87. (PMID: 15367883)
      Am J Physiol Cell Physiol. 2001 Aug;281(2):C532-43. (PMID: 11443052)
      Clin Cancer Res. 2004 Nov 1;10(21):7427-37. (PMID: 15534120)
      Eur J Surg Oncol. 2009 Aug;35(8):826-32. (PMID: 19041213)
      Cancer Res. 2008 Feb 1;68(3):918-26. (PMID: 18245495)
      Am J Pathol. 2000 Apr;156(4):1235-43. (PMID: 10751349)
      Am J Pathol. 2009 Mar;174(3):746-61. (PMID: 19234134)
      Nat Rev Cancer. 2006 May;6(5):392-401. (PMID: 16572188)
      Cancer Sci. 2009 Dec;100(12):2309-17. (PMID: 19735487)
      J Clin Invest. 2005 Feb;115(2):209-18. (PMID: 15690074)
      Nat Cell Biol. 2011 Dec 18;14(2):159-67. (PMID: 22179046)
      Cytokine Growth Factor Rev. 2007 Jun-Aug;18(3-4):245-56. (PMID: 17531524)
      Gastroenterology. 2010 Sep;139(3):1041-51, 1051.e1-8. (PMID: 20685603)
      Gut. 2002 Apr;50(4):535-41. (PMID: 11889076)
      Cell Tissue Res. 2008 Jun;332(3):479-88. (PMID: 18401596)
      Lancet. 2011 Aug 13;378(9791):607-20. (PMID: 21620466)
      Mol Cancer Ther. 2007 Apr;6(4):1186-97. (PMID: 17406031)
    • Accession Number:
      0 (NGFR protein, human)
      0 (Nerve Tissue Proteins)
      0 (RNA, Messenger)
      0 (Receptors, Nerve Growth Factor)
    • Publication Date:
      Date Created: 20130110 Date Completed: 20130627 Latest Revision: 20211021
    • Publication Date:
      20221213
    • Accession Number:
      PMC3531333
    • Accession Number:
      10.1371/journal.pone.0052682
    • Accession Number:
      23300742